Cargando…

Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup

BACKGROUND: Mammography can identify calcifications up to 50–100 μm in size as a surrogate parameter for breast cancer or ductal carcinoma in situ (DCIS). Microcalcifications measuring <50 µm are also associated with breast cancer or DCIS and are frequently not detected on mammography, although t...

Descripción completa

Detalles Bibliográficos
Autores principales: Emons, Julius, Fasching, Peter A., Wunderle, Marius, Heindl, Felix, Rieger, Jens, Horn, Florian, Pelzer, Georg, Ritter, Andre, Weber, Thomas, Radicke, Marcus, Polifka, Iris, Wachter, David L., Wenkel, Evelyn, Michel, Thilo, Uder, Michael, Hartmann, Arndt, Anton, Gisela, Beckmann, Matthias W., Schulz-Wendtland, Rüdiger, Jud, Sebastian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502853/
https://www.ncbi.nlm.nih.gov/pubmed/32994806
http://dx.doi.org/10.1177/1758835920957932
_version_ 1783584277496070144
author Emons, Julius
Fasching, Peter A.
Wunderle, Marius
Heindl, Felix
Rieger, Jens
Horn, Florian
Pelzer, Georg
Ritter, Andre
Weber, Thomas
Radicke, Marcus
Polifka, Iris
Wachter, David L.
Wenkel, Evelyn
Michel, Thilo
Uder, Michael
Hartmann, Arndt
Anton, Gisela
Beckmann, Matthias W.
Schulz-Wendtland, Rüdiger
Jud, Sebastian M.
author_facet Emons, Julius
Fasching, Peter A.
Wunderle, Marius
Heindl, Felix
Rieger, Jens
Horn, Florian
Pelzer, Georg
Ritter, Andre
Weber, Thomas
Radicke, Marcus
Polifka, Iris
Wachter, David L.
Wenkel, Evelyn
Michel, Thilo
Uder, Michael
Hartmann, Arndt
Anton, Gisela
Beckmann, Matthias W.
Schulz-Wendtland, Rüdiger
Jud, Sebastian M.
author_sort Emons, Julius
collection PubMed
description BACKGROUND: Mammography can identify calcifications up to 50–100 μm in size as a surrogate parameter for breast cancer or ductal carcinoma in situ (DCIS). Microcalcifications measuring <50 µm are also associated with breast cancer or DCIS and are frequently not detected on mammography, although they can be detected with dark-field imaging. This study examined whether additional breast examination using X-ray dark-field imaging can increase the detection rate of calcifications. Advances in knowledge:  (1) evaluation of additional modality of breast imaging;  (2) specific evaluation of breast calcifications. Implications for patient care: the addition of X-ray dark-field imaging to conventional mammography could detect additional calcifications. METHODS: Talbot–Lau X-ray phase–contrast imaging and X-ray dark-field imaging were used to acquire images of breast specimens. The radiation dosage with the technique is comparable with conventional mammography. Three X-ray gratings with periods of 5–10 µm between the X-ray tube and the flat-panel detector provide three different images in a single sequence: the conventional attenuation image, differential phase image, and dark-field image. The images were read by radiologists. Radiological findings were marked and examined pathologically. The results were described in a descriptive manner. RESULTS: A total of 81 breast specimens were investigated with the two methods; 199 significant structures were processed pathologically, consisting of 123 benign and 76 malignant lesions (DCIS or invasive breast cancer). X-ray dark-field imaging identified 15 additional histologically confirmed carcinoma lesions that were visible but not declared suspicious on digital mammography alone. Another four malignant lesions that were not visible on mammography were exclusively detected with X-ray dark-field imaging. CONCLUSIONS: Adding X-ray dark-field imaging to digital mammography increases the detection rate for breast cancer and DCIS associated lesions with micrometer-sized calcifications. The use of X-ray dark-field imaging may be able to provide more accurate and detailed radiological classification of suspicious breast lesions. Adding X-ray dark-field imaging to mammography may be able to increase the detection rate and improve preoperative planning in deciding between mastectomy or breast-conserving therapy, particularly in patients with invasive lobular breast cancer.
format Online
Article
Text
id pubmed-7502853
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75028532020-09-28 Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup Emons, Julius Fasching, Peter A. Wunderle, Marius Heindl, Felix Rieger, Jens Horn, Florian Pelzer, Georg Ritter, Andre Weber, Thomas Radicke, Marcus Polifka, Iris Wachter, David L. Wenkel, Evelyn Michel, Thilo Uder, Michael Hartmann, Arndt Anton, Gisela Beckmann, Matthias W. Schulz-Wendtland, Rüdiger Jud, Sebastian M. Ther Adv Med Oncol Original Research BACKGROUND: Mammography can identify calcifications up to 50–100 μm in size as a surrogate parameter for breast cancer or ductal carcinoma in situ (DCIS). Microcalcifications measuring <50 µm are also associated with breast cancer or DCIS and are frequently not detected on mammography, although they can be detected with dark-field imaging. This study examined whether additional breast examination using X-ray dark-field imaging can increase the detection rate of calcifications. Advances in knowledge:  (1) evaluation of additional modality of breast imaging;  (2) specific evaluation of breast calcifications. Implications for patient care: the addition of X-ray dark-field imaging to conventional mammography could detect additional calcifications. METHODS: Talbot–Lau X-ray phase–contrast imaging and X-ray dark-field imaging were used to acquire images of breast specimens. The radiation dosage with the technique is comparable with conventional mammography. Three X-ray gratings with periods of 5–10 µm between the X-ray tube and the flat-panel detector provide three different images in a single sequence: the conventional attenuation image, differential phase image, and dark-field image. The images were read by radiologists. Radiological findings were marked and examined pathologically. The results were described in a descriptive manner. RESULTS: A total of 81 breast specimens were investigated with the two methods; 199 significant structures were processed pathologically, consisting of 123 benign and 76 malignant lesions (DCIS or invasive breast cancer). X-ray dark-field imaging identified 15 additional histologically confirmed carcinoma lesions that were visible but not declared suspicious on digital mammography alone. Another four malignant lesions that were not visible on mammography were exclusively detected with X-ray dark-field imaging. CONCLUSIONS: Adding X-ray dark-field imaging to digital mammography increases the detection rate for breast cancer and DCIS associated lesions with micrometer-sized calcifications. The use of X-ray dark-field imaging may be able to provide more accurate and detailed radiological classification of suspicious breast lesions. Adding X-ray dark-field imaging to mammography may be able to increase the detection rate and improve preoperative planning in deciding between mastectomy or breast-conserving therapy, particularly in patients with invasive lobular breast cancer. SAGE Publications 2020-09-18 /pmc/articles/PMC7502853/ /pubmed/32994806 http://dx.doi.org/10.1177/1758835920957932 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Emons, Julius
Fasching, Peter A.
Wunderle, Marius
Heindl, Felix
Rieger, Jens
Horn, Florian
Pelzer, Georg
Ritter, Andre
Weber, Thomas
Radicke, Marcus
Polifka, Iris
Wachter, David L.
Wenkel, Evelyn
Michel, Thilo
Uder, Michael
Hartmann, Arndt
Anton, Gisela
Beckmann, Matthias W.
Schulz-Wendtland, Rüdiger
Jud, Sebastian M.
Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup
title Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup
title_full Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup
title_fullStr Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup
title_full_unstemmed Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup
title_short Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup
title_sort assessment of the additional clinical potential of x-ray dark-field imaging for breast cancer in a preclinical setup
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502853/
https://www.ncbi.nlm.nih.gov/pubmed/32994806
http://dx.doi.org/10.1177/1758835920957932
work_keys_str_mv AT emonsjulius assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT faschingpetera assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT wunderlemarius assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT heindlfelix assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT riegerjens assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT hornflorian assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT pelzergeorg assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT ritterandre assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT weberthomas assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT radickemarcus assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT polifkairis assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT wachterdavidl assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT wenkelevelyn assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT michelthilo assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT udermichael assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT hartmannarndt assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT antongisela assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT beckmannmatthiasw assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT schulzwendtlandrudiger assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup
AT judsebastianm assessmentoftheadditionalclinicalpotentialofxraydarkfieldimagingforbreastcancerinapreclinicalsetup